- Home
- NDMO vs IMNM Comparison
NDMO vs IMNM Comparison
Compare NDMO & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NDMO | IMNM |
|---|---|---|
| Founded | 2019 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 622.4M | 1.8B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NDMO | IMNM |
|---|---|---|
| Price | $10.21 | $21.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $31.44 |
| AVG Volume (30 Days) | 218.6K | ★ 3.0M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 6.75% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,679,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $11.53 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.99 | $5.15 |
| 52 Week High | $11.24 | $25.30 |
Technical Indicators
Market Signals| Indicator | NDMO | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 46.78 | 55.72 |
| Support Level | $9.95 | $21.00 |
| Resistance Level | $10.22 | $22.57 |
| Average True Range (ATR) | 0.14 | 1.47 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 59.52 | 38.52 |
Price Performance
Historical ComparisonAbout NDMO Nuveen Dynamic Municipal Opportunities Fund of Beneficial Interest
Nuveen Dynamic Municipal Opportunities is a closed-end management investment company. Its investment objective is to seek total return through income exempt from regular federal income taxes and capital appreciation. A majority of its investments are made in municipal securities, the income from which is exempted from regular federal income taxes.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.